Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Benzinga · 4d ago
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $21 to $26.